Malignant gliomas continue to be a significant source of mortality in young and middle aged adults. The introduction of new treatment strategies and multidisciplinary approaches has improved the outcome of patients with these tumors only slightly. Because retinoic acid has growth inhibitory activity against glioma and neuroblastoma cells in cultures, we assessed the efficacy of all-trans-retinoic acid in the treatment of recurrent cerebral gliomas. Thirty-six patients with recurrent cerebral gliomas were entered in the study and treated with 120 or 150 mg/ m2/day of all-trans-retinoic acid as a single agent. The drug was given for 3 weeks followed with one week of rest. Two blocks of 4 weeks constituted one course of treatment. One (3%) of 34 evaluable patients had a minor response and 14 (41%) had stable disease. In the rest of the patients (56%), tumors continued to progress despite treatment. The median time to progression of all evaluable patients was 8 weeks, and for the responders was 17 weeks. The higher dose level (150 mg/m2) was associated with high incidence of headache, which responded to dose reduction. The lower dose level was very well tolerated, with mild, mainly dermatological toxicity. All-trans-retinoic acid as a single agent has no significant activity against recurrent cerebral gliomas.

译文

恶性神经胶质瘤仍然是中青年成年人死亡的重要来源。新的治疗策略和多学科方法的引入仅略微改善了这些肿瘤患者的预后。由于视黄酸对培养物中的神经胶质瘤和神经母细胞瘤细胞具有生长抑制活性,因此我们评估了全反式视黄酸在治疗复发性脑胶质瘤中的功效。36例复发性脑胶质瘤患者进入研究,并以120或150 mg/ m2/天的全反式维甲酸作为单一药物进行治疗。给药3周,然后休息一周。两个为期4周的块构成一个疗程。34名可评估患者中有1名 (3% 名) 反应轻微,14名 (41% 名) 疾病稳定。在其余患者 (56%) 中,尽管进行了治疗,但肿瘤仍在继续发展。所有可评估患者的中位进展时间为8周,应答者为17周。较高的剂量水平 (150 mg/m2) 与头痛的高发生率相关,头痛对剂量减少有反应。较低的剂量水平耐受性良好,具有轻度 (主要是皮肤病学毒性)。全反式维甲酸作为单一药物对复发性脑胶质瘤没有显着活性。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录